Blood levels of Trastuzumab Deruxtecan in Japanese patients with HER2-positive breast cancer

Blood levels of Trastuzumab Deruxtecan in Japanese patients with HER2-positive breast cancer - Blood levels of Trastuzumab Deruxtecan in Japanese patients with HER2-positive breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050460

Enrollment

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HER2-positive metastatic breast cancer patients undergoing or planning to be treated with Trastuzumab Deruxtecan

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Blood levels of Trastuzumab Deruxtecan	—

Secondary

Measure	Time frame
Comparison of Blood levels of Trastuzumab Deruxtecan to the drug dose and adverse events	—

Countries

Japan

Contacts

Public ContactIku Yamaga

NHO Kyoto Medical Center Department of Breast Surgery

ikuyamaga.kmc@gmail.com0756419161

Outcome results